TechXpress

IBS

To build drug-likeness properties into candidate molecules at an early stage, we will establish the efficacy of orally available small molecule macrophage migration inhibitory factor (MIF) inhibitors against IBDs in animal models. Should a suitable candidate(s) emerge from these studies, structural corrections for solubility, permeability, toxicity, and metabolic vulnerability are expected to be minimized, leading to a faster and more direct drug approval process.